ArticleJournal of molecular neuroscience : MN2019
Altered Cerebrospinal Fluid Concentrations of Hydrophobic and Hydrophilic Compounds in Early Stages of Multiple Sclerosis-Metabolic Profile Analyses.
Article in Journal of molecular neuroscience : MN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Metabolic Pattern of Brain Death-NMR-Based Metabolomics of Cerebrospinal Fluid.International journal of molecular sciences · 2025Article
- Recent Advances in Metabolomics and Lipidomics Studies in Human and Animal Models of Multiple Sclerosis.Metabolites · 2024Review
- NMR-based metabolomics identification of potential serum biomarkers of disease progression in patients with multiple sclerosis.Scientific reports · 2024Article
- Metabolomics of Cerebrospinal Fluid Amino and Fatty Acids in Early Stages of Multiple Sclerosis.International journal of molecular sciences · 2023Article
- Metabolite Alterations in Autoimmune Diseases: A Systematic Review of Metabolomics Studies.Metabolites · 2023Review
- Disease phenotype prediction in multiple sclerosis.iScience · 2023Article
- Fatty acids role in multiple sclerosis as "metabokines".Journal of neuroinflammation · 2022Review
- The potential roles of amino acids and their major derivatives in the management of multiple sclerosis.Amino acids · 2022Review
- Metabolomics of Cerebrospinal Fluid in Multiple Sclerosis Compared With Healthy Controls: A Pilot Study.Frontiers in neurology · 2022Article
- Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment.International journal of molecular sciences · 2021Review
- Relationship between amniotic fluid metabolic profile with fetal gender, maternal age, and gestational week.BMC pregnancy and childbirth · 2021Article
- An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview.Cellular and molecular life sciences : CMLS · 2021Review
- The effects of exercise training on lipid profile in patients with sarcoidosis.Scientific reports · 2021Observational
- Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach.Brain communications · 2021Article
- Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis.Metabolites · 2020Article
- Article
- Characterization of Postprandial Effects on CSF Metabolomics: A Pilot Study with Parallel Comparison to Plasma.Metabolites · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of a single predictive or diagnostic test in multiple sclerosis (MS) remains a major obstacle in the patient's care. The aim of this study was to investigate metabolic profiles, especially lipids in cerebrospinal fluid (CSF) using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.